Back to Search Start Over

Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma.

Authors :
Ailawadhi S
Panjabi S
Campioni M
Majer I
Jakubowiak A
Source :
Journal of managed care & specialty pharmacy [J Manag Care Spec Pharm] 2018 Jul; Vol. 24 (7), pp. 711-712.
Publication Year :
2018

Abstract

Disclosures: Ailawadhi reports research support from Pharmacyclics and consulting relationships with Takeda, Amgen, and Celgene. Jakubowiak reports consulting and advisory board relationships with AbbVie, Amgen, BMS, Celgene, Karyopharm, SkylineDX, and Takeda. Panjabi, Campioni, and Majer are employees of and stockholders in Amgen.

Subjects

Subjects :
Antineoplastic Combined Chemotherapy Protocols
Cost-Benefit Analysis
Humans
United States
Multiple Myeloma

Details

Language :
English
ISSN :
2376-1032
Volume :
24
Issue :
7
Database :
MEDLINE
Journal :
Journal of managed care & specialty pharmacy
Publication Type :
Editorial & Opinion
Accession number :
29952705
Full Text :
https://doi.org/10.18553/jmcp.2018.24.7.711
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details